Navigation Links
Verenium To Sponsor The Renewable Fuels Association 18th Annual National Ethanol Conference
Date:2/4/2013

SAN DIEGO, Feb. 4, 2013 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that the Company is a sponsor of the Renewable Fuels Association's (RFA) 18th Annual National Ethanol Conference.  The conference is taking place February 5 – 7, 2013 at the Wynn Las Vegas in Las Vegas, Nevada.

(Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO)

The RFA's National Ethanol Conference is recognized as one of the premier forums for the ethanol industry to come together and work to address the current market situation and issues facing the industry.  Verenium is pleased to support such an important event and to be part of the discussion on how products like Verenium's Fuelzyme® alpha-amylase enzyme, can help ethanol producers recognize multiple sources of savings such as reduced chemical usage and dose reduction, and improve plant profitability in tough market conditions.

To learn more about Fuelzyme® alpha-amylase and Verenium's other grain processing enzyme solutions, look for product information on the sponsor table at the upcoming 18th Annual RFA National Ethanol Conference or contact Verenium Customer Relations at enzymes@verenium.com and 1.800.523.2990.

For more information on the RFA's National Ethanol Conference visit http://www.nationalethanolconference.com/.  

About Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward Looking Statements for Verenium
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's ability to commercialize its products, enhance its manufacturing capabilities, capture near-term and longer-term growth and prospects, and reach profitability.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, products and product candidates and product pipeline (including Verenium's ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, and market demand for those products and product candidates), dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture or partnership agreements and licenses on a timely basis or at all, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2011 and any updates contained in its subsequently filed quarterly reports on Form 10-Q .  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts for Verenium:

Sarah Carmody

Sr. Corporate Communications Manager

858-431-8581

sarah.carmody@verenium.com



'/>"/>
SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
2. Verenium to Present at Baird Clean Technology Conference
3. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
4. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
5. Verenium Corporation To Announce First Quarter 2012 Financial Results
6. Verenium Corporation Named One Of The 2012 Best Places to Work in San Diego
7. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
8. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
9. Verenium Corporation To Announce Second Quarter 2012 Financial Results
10. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
11. Verenium Corporation To Announce Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)...   ViaCyte, Inc ., a leading, privately-held ... cell-derived islet replacement therapy for the treatment of ... that ViaCyte and Janssen Biotech, Inc., one of ... have agreed to consolidate the assets of the ... ViaCyte with an exclusive license to all BetaLogics ...
(Date:2/3/2016)... BRUNSWICK, N.J. , Feb. 3, 2016 /PRNewswire-USNewswire/ ... grants totaling more than $1 million for researchers ... are working on health-related research that demonstrates exciting ... this round of funding for the New Jersey ... for faculty members at these educational institutions— Princeton ...
(Date:2/3/2016)... MEDFORD, Mass. , Feb. 3, 2016  Silk Therapeutics, ... A2 financing round. Silk Therapeutics has now raised a total ... progress made by the company. The Series A2 round was ... Foxboro, Massachusetts , with participation from new investors Lear ... Sheri and Roy P. Disney ; Richard Sackler ...
(Date:2/3/2016)... ... February 03, 2016 , ... Big games come and go, but ... much for our country. CereScan, a nationally recognized brain diagnostics and technology company, will ... Football Team (WWAFT) vs. NFL Stars Flag Football Game on February 6, 2016. ...
Breaking Biology Technology:
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016 ... innovative sensor-based diagnostic products, today announced the closing of a ... existing investors.  Proceeds from the financing will be used to ... hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction has ...
(Date:1/7/2016)... , Jan. 7, 2016 This BCC Research ... for biometric technologies and devices, identifying newer markets and ... various types of biometric devices. Includes forecast from 2015 ... Identify newer markets and explore the expansion of the ... Examine each type of biometric technology, determine its current ...
(Date:1/7/2016)... -- A United States District Court in Illinois ... to interpret a biometric privacy statute in a decision ... photo website Shutterfly brought by the law firm Carey Rodriguez ... SHUTTERFLY, INC.; and THISLIFE, INC ( N.D. Ill ., ... Illinois Biometric Privacy Act by collecting and scanning face ...
Breaking Biology News(10 mins):